Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Centanafadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 10/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Centanafadine SCHEMBL17911611 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL4187417 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL13698169 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL4177088 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL13698302 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL16214791 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL4194713 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL13698168 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL16213933 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL30033872 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375418-A1 | 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER | OTSUKA PHARMA CO LTD (JP) | 2025-12-11 | — | — | US | disclosed |
| EP-4580605-A1 | 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-07-09 | — | — | EP | disclosed |
| CN-119907663-A | Comprises Sentanafadine pharmaceutical composition of (2) | 大塚制药株式会社 | 2025-04-29 | — | — | CN | disclosed |
| CN-119730840-A | 1- (Naphthalen-2-yl) -3-azabicyclo [3.1.0] hexane for the treatment of major depressive disorder | 大塚制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| CN-119730840-A | 1- (Naphthalen-2-yl) -3-azabicyclo [3.1.0] hexane for the treatment of major depressive disorder | 大塚制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| WO-2024048782-A1 | 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-03-07 | — | — | WO | disclosed |
| CN-117466800-A | Crystalline compounds | 大塚制药美国公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117480153-A | Azabicyclo [3.1.0] hexane compounds | 大塚制药株式会社 | 2024-01-30 | — | — | CN | disclosed |
| CN-117088802-A | Crystalline compounds | 大塚制药美国公司 | 2023-11-21 | — | — | CN | disclosed |
| WO-2022265020-A1 | AZABICYCLO[3.1.0]HEXANE COMPOUND | 大塚製薬株式会社 | 2022-12-22 | — | — | WO | disclosed |
| US-20220347157-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING (1R, 5S)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2022-11-03 | — | — | US | disclosed |
| CN-114555557-A | Process for preparing sertraline | 大塚制药株式会社 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220347157-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING (1R, 5S)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE | ABCB11, NAP1L1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A2 212/4885SLC6A4 487/4885SLC6A3 587/4885 |
| US-20250375418-A1 | 1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE FOR TREATING MAJOR DEPRESSIVE DISORDER | HTR1B, HTR1D, HTR1A | SLC6A2 5/4885SLC6A4 26/4885SLC6A3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.